$10.29
3.29% today
Nasdaq, Sep 08, 08:45 pm CET
ISIN
US8162121045
Symbol
RNAC

Cartesian Therapeutics Stock price

$10.64
-1.19 10.06% 1M
-7.28 40.63% 6M
-7.27 40.59% YTD
-3.40 24.22% 1Y
-16.81 61.24% 3Y
-22.06 67.46% 5Y
-199.36 94.93% 10Y
-199.36 94.93% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+0.64 6.40%
ISIN
US8162121045
Symbol
RNAC
Industry

Key metrics

Basic
Market capitalization
$276.7m
Enterprise Value
$116.3m
Net debt
positive
Cash
$160.3m
Shares outstanding
26.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
148.7 | 145.4
EV/Sales
62.6 | 61.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1.6%
Return on Equity
1,138.3%
ROCE
-23.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.9m | $1.9m
EBITDA
$-85.5m | -
EBIT
$-88.0m | $-96.2m
Net Income
$-38.9m | $-56.6m
Free Cash Flow
$-44.5m
Growth (TTM | estimate)
Revenue
-96.6% | -95.1%
EBITDA
-77.5% | -
EBIT
-79.6% | -164.8%
Net Income
83.4% | 26.9%
Free Cash Flow
31.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,591.3% | -
EBIT
-4,726.4%
Net
-2,088.5% | -2,973.0%
Free Cash Flow
-2,390.7%
More
EPS
$-1.5
FCF per Share
$-1.7
Short interest
22.9%
Employees
66
Rev per Employee
$590.0k
Show more

Is Cartesian Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Cartesian Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Cartesian Therapeutics forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Cartesian Therapeutics forecast:

Buy
80%
Hold
20%

Financial data from Cartesian Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.86 1.86
97% 97%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
35% 35%
1,570%
- Research and Development Expense 52 52
9% 9%
2,809%
-85 -85
78% 78%
-4,596%
- Depreciation and Amortization 2.52 2.52
200% 200%
135%
EBIT (Operating Income) EBIT -88 -88
80% 80%
-4,732%
Net Profit -39 -39
83% 83%
-2,091%

In millions USD.

Don't miss a Thing! We will send you all news about Cartesian Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cartesian Therapeutics Stock News

Neutral
GlobeNewsWire
11 days ago
FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
Neutral
The Motley Fool
about one month ago
Cartesian (RNAC) Q2 Revenue Drops 99%
Neutral
GlobeNewsWire
3 months ago
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's co...
More Cartesian Therapeutics News

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Head office United States
CEO Carsten Brunn
Employees 66
Founded 2007
Website www.cartesiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today